Upadacitinib (Rinvoq, AbbVie) in Severe AA: Explore the Topline Phase 3 Data
Upadacitinib (Rinvoq, AbbVie) performed well in severe alopecia areata (AA), according to topline data from the first of two pivotal studies of the Phase 3 UP-AA clinical program.